Role of moxifloxacin for the treatment of commmunity-acquired complicated intra-abdominal infections in Taiwan

Journal of Microbiology, Immunology and Infection

Volumn 45, Issue 1, 2012, Pages 1-6

  Lau, Yeu Jun ^a   Chen, Yen Hsu ^b   Huang, Ching Tai ^c   Lee, Wen Sen ^d   Liu, Cheng Yi ^e   Liu, Jien Wei ^f   Liu, Hsiao Dong ^g   Lee, Yuarn Jang ^h   Chen, Chao Wen ^b   Ko, Wen Chien ⁱ   Hsueh, Po Ren ^j  

^a SHOW CHWAN MEMORIAL HOSPITAL   (Taiwan)

^b KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^c CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

^d TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^e TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^f CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^g EN CHU KONG HOSPITAL   (Taiwan)

^h TAIPEI MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

ⁱ NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

^j NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

more..

Author keywords

Antimicrobial therapy; Complicated intra abdominal infections; Fluoroquinolones; Moxifloxacin

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; CEFTRIAXONE; CIPROFLOXACIN; ERTAPENEM; LEVOFLOXACIN; METRONIDAZOLE; MOXIFLOXACIN; PIPERACILLIN PLUS TAZOBACTAM;

ABDOMINAL INFECTION; ABSCESS; ACINETOBACTER BAUMANNII; ACUTE ABDOMEN; ACUTE APPENDICITIS; ACUTE CHOLECYSTITIS; AEROMONAS HYDROPHILA; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; ANTIMICROBIAL ACTIVITY; BACTEROIDES FRAGILIS; CHOLECYSTITIS; COMMUNITY ACQUIRED COMPLICATED INTRAABDOMINAL INFECTION; COMPLICATED INTRAABDOMINAL INFECTION; DIVERTICULITIS; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; ENTEROBACTER; ESCHERICHIA COLI; HUMAN; KLEBSIELLA; MINIMUM INHIBITORY CONCENTRATION; MONOTHERAPY; NONHUMAN; PATHOGENESIS; PERITONITIS; PHASE 3 CLINICAL TRIAL (TOPIC); PSEUDOMONAS AERUGINOSA; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; TAIWAN; TIME TO MAXIMUM PLASMA CONCENTRATION; UNSPECIFIED SIDE EFFECT;

ANTI-BACTERIAL AGENTS; ASIA; AZA COMPOUNDS; COMMUNITY-ACQUIRED INFECTIONS; ENTEROBACTERIACEAE INFECTIONS; GUIDELINES AS TOPIC; HUMANS; INTRAABDOMINAL INFECTIONS; QUINOLINES; TREATMENT OUTCOME;

EID: 84862827681     PISSN: 16841182     EISSN: 19959133     Source Type: Journal    
DOI: 10.1016/j.jmii.2011.11.010     Document Type: Review

References (28)

1. Solomkin J.S., Mazuski J.E., Bradley J.S., Rodvold K.A., Goldstein E.J., Baron E.J., et al. Diagnosis and management of complicated intra-abdominal infection in adults and children: guidelines by the Surgical Infection Society and the Infectious Diseases Society of America. Clin Infect Dis 2010, 50:133-164.
2. Solomkin J.S., Mazuski J.E., Bradley J.S., Rodvold K.A., Goldstein E.J., Baron E.J., et al. Diagnosis and management of complicated intra-abdominal infection in adults and children: guidelines by the Surgical Infection Society and the Infectious Diseases Society of America. Surg Infect (Larchmt) 2010, 11:79-109.
3. Hsueh P.R., Hawkey P.M. Consensus statement on antimicrobial therapy of intra-abdominal infections in Asia. Int J Antimicrob Agents 2007, 30:129-133.
4. Liu C.D., McFadden D.W. Acute abdomen and appendix. Surgery: scientific principles and practice 1997, 1246-1261. Lippincott-Raven Publishers, Philadelphia. 2nd ed. L.J. Greenfield, M.W. Mulholland, K.T. Oldham, G.B. Zelenock (Eds.).
5. Marshall J.C. Intra-abdominal infections. Microbes Infect 2004, 6:1015-1025.
6. Solomkin J.S., Hemsell D.L., Sweet R., Tally F., Bartlett J. Evaluation of new anti-infective drugs for the treatment of intraabdominal infections. Infectious Diseases Society of America and the Food and Drug Administration. Clin Infect Dis 1992, 15(suppl. 1):S33-S42.
7. Goldstein E.J., Snydman D.R. Intra-abdominal infections: review of the bacteriology, antimicrobial susceptibility and the role of ertapenem in their therapy. J Antimicrob Chemother 2004, 53(suppl. 2):ii29-ii36.
8. Evans H.L., Raymond D.P., Pelletier S.J., Crabtree T.D., Pruett T.L., Sawyer R.G. Diagnosis of intra-abdominal infection in the critically ill patient. Curr Opin Crit Care 2001, 7:117-121.
9. Mazuski J.E., Sawyer R.G., Nathens A.B., DiPiro J.T., Schein M., Kudsk K.A., et al. The Surgical Infection Society guidelines on antimicrobial therapy for intra-abdominal infections: an executive summary. Surg Infect 2002, 3:161-173.
10. Blot S., De Waele J.J. Critical issues in the clinical management of complicated intra-abdominal infections. Drugs 2005, 65:1611-1620.
11. Goldstein E.J. Intra-abdominal anaerobic infections: bacteriology and therapeutic potential of newer antimicrobial carbapenem, fluoroquinolone, and desfluoroquinolone therapeutic agents. Clin Infect Dis 2002, 35(Suppl 1):S106-S111.
12. Malangoni M.A., Song J., Herrington J., Choudhri S., Pertel P. Randomized controlled trial of moxifloxacin compared with piperacillin-tazobactam and amoxicillin-clavulanate for the treatment of complicated intra-abdominal infections. Ann Surg 2006, 244:204-211.
13. Chow J.W., Satishchandran V., Snyder T.A., Harvey C.M., Friedland I.R., Dinubile M.J. Invitro susceptibilities of aerobic and facultative gram-negative bacilli isolated from patients with intra-abdominal infections worldwide: the 2002 Study for Monitoring Antimicrobial Resistance Trends (SMART). Surg Infect (Larchmt) 2005, 6:439-448.
14. Chen Y.H., Hsueh P.R., Badal R.E., Hawser S.P., Hoban D.J., Bouchillon S.K., et al. Antimicrobial susceptibility profiles of aerobic and facultative Gram-negative bacilli isolated from patients with intra-abdominal infections in the Asia-Pacific region according to currently established susceptibility interpretive criteria. J Infect 2011, 62:280-291.
15. Chen W.Y., Jang T.N., Huang C.H., Hsueh P.R. Invitro susceptibilities of aerobic and facultative anaerobic Gram-negative bacilli isolated from patients with intra-abdominal infections at a medical center in Taiwan: results of the Study for Monitoring Antimicrobial Resistance Trends (SMART) 2002-2006. J Microbiol Immunol Infect 2009, 42:317-323.
16. Edmiston C.E., Krepel C.J., Seabrook G.R., Somberg L.R., Nakeeb A., Cambria R.A., et al. Invitro activities of moxifloxacin against 900 aerobic and anaerobic surgical isolates from patients with intra-abdominal and diabetic foot infections. Antimicrob Agents Chemother 2004, 48:1012-1016.
17. Liu C.Y., Lu C.L., Huang Y.T., Liao C.H., Hsueh P.R. Invitro activities of moxifloxacin and tigecycline against bacterial isolates associated with intra-abdominal infections at a medical center in Taiwan, 2001-2006. Eur J Clin Microbiol Infect Dis 2009, 28:1437-1442.
18. Liu C.Y., Huang Y.T., Liao C.H., Yen L.C., Lin H.Y., Hsueh P.R. Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems. Antimicrob Agents Chemother 2008, 52:3161-3168.
19. Krobot K., Yin D., Zhang Q., Sen S., Altendorf-Hofmann A., Scheele J., et al. Effect of inappropriate initial empiric antibiotic therapy on outcome of patients with community-acquired intra-abdominal infections requiring surgery. Eur J Clin Microbiol Infect Dis 2004, 23:682-687.
20. Stein G.E., Schooley S., Tyrrell K.L., Citron D.M., Nicolau D.P., Goldstein E.J. Serum bactericidal activities of moxifloxacin and levofloxacin against aerobic and anaerobic intra-abdominal pathogens. Anaerobe 2008, 14:8-12.
21. Wirtz M., Kleeff J., Swoboda S., Halaceli I., Geiss H.K., Hoppe-Tichy T., et al. Moxifloxacin penetration into human gastrointestinal tissues. J Antimicrob Chemother 2004, 53:875-877.
22. Stass H., Rink A.D., Delesen H., Kubitza D., Vestweber K.H. Pharmacokinetics and peritoneal penetration of moxifloxacin in peritonitis. J Antimicrob Chemother 2006, 58:693-696.
23. Wacke R., Forster S., Adam U., Mundkowski R.G., Klar E., Hopt U.T., et al. Penetration of moxifloxacin into the human pancreas following a single intravenous or oral dose. J Antimicrob Chemother 2006, 58:994-999.
24. Rink A.D., Stass H., Delesen H., Kubitza D., Vestweber K.H. Pharmacokinetics and tissue penetration of moxifloxacin in intervention therapy for intra-abdominal abscess. Clin Drug Investig 2008, 28:71-79.
25. Weiss G., Reimnitz P., Hampel B., Muehlhofer E., Lippert H. AIDA Study Group. Moxifloxacin for the treatment of patients with cIAI, the AIDA study. J Chemother 2009, 21:170-180.
26. Solomkin J., Zhao Y.P., Ma E.L., Chen M.J., Hampel B. DRAGON study team. Moxifloxacin is non-inferior to combination therapy with ceftriaxone plus metronidazole in patients with community-origin complicated intra-abdominal infections. Int J Antimicrob Agents 2009, 34:439-445.
27. De Waele J., Tellado J., Alder J., Reimnitz P., Jensen M., Hampel B., et al. Efficacy and safety of moxifloxacin versus ertapenem in complicated intra-abdominal infections: results of the PROMISE study 2010, European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), Vienna, Austria, Abstract P1549.
28. Goldstein E.J., Solomkin J.S., Citron D.M., Alder J.D. Clinical efficacy and correlation of clinical outcomes with invitro susceptibility for anaerobic bacteria in patients with complicated intra-abdominal infections treated with moxifloxacin. Clin Infect Dis 2011 Oct 12, Epub.